The immune system constantly scans the body for tumor cells, destroying most of them before they can become a detectable cancer, but sometimes it needs a boost. That’s the thinking behind the new generation of cancer treatments called immunotherapies. One of the most promising versions are CAR-Ts (chimeric antigen receptor T cells).
Two CAR-Ts have been approved by the Food and Drug Administration: Yescarta, developed Kite Pharma (which was bought by Gilead), is used to treat adult patients with certain types of large B-cell lymphoma, and Kymriah, from Novartis, is for a form of acute lymphoblastic leukemia.
Please forward any new Information
I am a big fan of Sharon Begley. I try to read everything by her that I come across. But – subscribe to Stat Plus would just add more emails that I don’t have time to read. I read Megan five days a week, and I often read articles she recommends, but I also read a great many other things and Medicine is not my primary interest. Please don’t do this again. I know you want in increase Stat Plus’ members but please understand that everyone’s time is limited.
Comments are closed.